NEW YORK, Feb 6 – Third Wave Technologies said Tuesday it would supply its Invader SNP detection and gene expression system to the University of Wisconsin, Madison in exchange for rights to commercialize certain discoveries for research, diagnostic, or therapeutic purposes.
" This is yet another initiative to expand the reach of our platform to identify valuable targets that may be useful in identifying the genetic cause of diseases and therapeutic candidates for treatment," Lance Fors, Third Wave CEO, said in a statement.
Fors said he expects the collaboration to help speed up discoveries linking genetics to disease.
Third Wave’s other deals include agreements with Glaxo-SmithKline, Novartis, Pfizer, and the Sanger Center.
The company’s initial public offering is expected to take place by the middle of February.